Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 752 of 752

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Ranibizumab for treating diabetic macular oedemaTA274
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Deucravacitinib for treating moderate to severe plaque psoriasisTA907
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Tezepelumab for treating severe asthmaTA880
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Upadacitinib for treating moderately to severely active ulcerative colitisTA856
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Cabozantinib for previously treated advanced hepatocellular carcinomaTA849
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)TA839
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)TA834
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Upadacitinib for treating active ankylosing spondylitisTA829
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Brolucizumab for treating diabetic macular oedemaTA820
Avalglucosidase alfa for treating Pompe diseaseTA821
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney diseaseTA809
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglyceridesTA805
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Roxadustat for treating symptomatic anaemia in chronic kidney diseaseTA807
Fenfluramine for treating seizures associated with Dravet syndromeTA808
Teduglutide for treating short bowel syndromeTA804
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Filgotinib for treating moderately to severely active ulcerative colitisTA792
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Dapagliflozin for treating chronic kidney diseaseTA775
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA776
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Palforzia for treating peanut allergy in children and young peopleTA769
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA599
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Cabotegravir with rilpivirine for treating HIV-1TA757
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsyTA758
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA756
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Cenobamate for treating focal onset seizures in epilepsyTA753
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Upadacitinib for treating moderate rheumatoid arthritisTA744
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Selpercatinib for treating advanced thyroid cancer with RET alterationsTA742
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Tofacitinib for treating juvenile idiopathic arthritisTA735
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA733
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)TA731
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Midostaurin for treating advanced systemic mastocytosisTA728
Sapropterin for treating hyperphenylalaninaemia in phenylketonuriaTA729
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA722
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndromeTA139
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphomaTA720
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancerTA721
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating axial spondyloarthritisTA718
Secukinumab for treating non-radiographic axial spondyloarthritisTA719
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillationTA249
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillationTA256
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA355
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitisTA708
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Ravulizumab for treating atypical haemolytic uraemic syndromeTA710
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)TA700
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA696
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Avelumab for treating metastatic Merkel cell carcinomaTA517
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinomaTA666
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpuraTA667
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA663
Liraglutide for managing overweight and obesityTA664
Upadacitinib for treating severe rheumatoid arthritisTA665
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerTA660
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Drug-eluting stents for the treatment of coronary artery diseaseTA152
Guidance on the use of coronary artery stentsTA71
Siponimod for treating secondary progressive multiple sclerosisTA656
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Galcanezumab for preventing migraineTA659
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA648
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Avelumab with axitinib for untreated advanced renal cell carcinomaTA645
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Entrectinib for treating NTRK fusion-positive solid tumoursTA644
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Ustekinumab for treating moderately to severely active ulcerative colitisTA633
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Larotrectinib for treating NTRK fusion-positive solid tumoursTA630
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximabTA629
Lenalidomide with rituximab for previously treated follicular lymphomaTA627
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)TA625
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisTA624
Patiromer for treating hyperkalaemiaTA623
Sotagliflozin with insulin for treating type 1 diabetesTA622
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA617
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Cannabidiol with clobazam for treating seizures associated with Dravet syndromeTA614
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndromeTA615
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pentosan polysulfate sodium for treating bladder pain syndromeTA610
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA611
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseTA607
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)TA594
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590
Letermovir for preventing cytomegalovirus disease after a stem cell transplantTA591
Nusinersen for treating spinal muscular atrophyTA588
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityTA589
Bisphosphonates for treating osteoporosisTA464
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormalityTA322
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetesTA572
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Cochlear implants for children and adults with severe to profound deafnessTA566
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaTA562
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Regorafenib for previously treated advanced hepatocellular carcinomaTA555
Darvadstrocel for treating complex perianal fistulas in Crohn's diseaseTA556
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 yearsTA554
Lenvatinib for untreated advanced hepatocellular carcinomaTA551
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemiaTA552
Vandetanib for treating medullary thyroid cancerTA550
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)TA548
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Tofacitinib for moderately to severely active ulcerative colitisTA547
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Cabozantinib for untreated advanced renal cell carcinomaTA542
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Dinutuximab beta for treating neuroblastomaTA538
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Dupilumab for treating moderate to severe atopic dermatitisTA534
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapyTA530
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's diseaseTA217
Guselkumab for treating moderate to severe plaque psoriasisTA521
Midostaurin for untreated acute myeloid leukaemiaTA523
Brentuximab vedotin for treating CD30-positive Hodgkin lymphomaTA524
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA525
Arsenic trioxide for treating acute promyelocytic leukaemiaTA526
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Tocilizumab for treating giant cell arteritisTA518
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Cabozantinib for treating medullary thyroid cancerTA516
Brodalumab for treating moderate to severe plaque psoriasisTA511
Tivozanib for treating advanced renal cell carcinomaTA512
Obinutuzumab for untreated advanced follicular lymphomaTA513
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the kneeTA508
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis CTA507
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal womenTA160
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal womenTA161
Pirfenidone for treating idiopathic pulmonary fibrosisTA504
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Ibrutinib for treating relapsed or refractory mantle cell lymphomaTA502
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Lenvatinib with everolimus for previously treated advanced renal cell carcinomaTA498
Glecaprevir–pibrentasvir for treating chronic hepatitis CTA499
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Golimumab for treating non-radiographic axial spondyloarthritisTA497
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerTA476
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)TA468
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)TA469
Holoclar for treating limbal stem cell deficiency after eye burnsTA467
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Cabozantinib for previously treated advanced renal cell carcinomaTA463
Baricitinib for moderate to severe rheumatoid arthritisTA466
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Roflumilast for treating chronic obstructive pulmonary diseaseTA461
Nivolumab for treating relapsed or refractory classical Hodgkin lymphomaTA462
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Ustekinumab for moderately to severely active Crohn's disease after previous treatmentTA456
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Etelcalcetide for treating secondary hyperparathyroidismTA448
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive diseaseTA449
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaTA450
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaTA451
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Obeticholic acid for treating primary biliary cholangitisTA443
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for the treatment of adults with moderate to severe psoriasisTA180
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429
Sofosbuvir–velpatasvir for treating chronic hepatitis CTA430
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemiaTA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaTA426
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitorsTA407
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutationTA398
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA394
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaTA396
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetesTA390
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fractionTA388
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancerTA389
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosisTA386
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)TA23
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemiaTA385
Nivolumab for treating advanced (unresectable or metastatic) melanomaTA384
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritisTA383
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA377
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyTA378
Nintedanib for treating idiopathic pulmonary fibrosisTA379
Panobinostat for treating multiple myeloma after at least 2 previous treatmentsTA380
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)TA382
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Guidance on the use of imatinib for chronic myeloid leukaemiaTA70
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tearsTA369
Bortezomib for previously untreated mantle cell lymphomaTA370
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis CTA365
Vortioxetine for treating major depressive episodesTA367
Ledipasvir–sofosbuvir for treating chronic hepatitis CTA363
Tolvaptan for treating autosomal dominant polycystic kidney diseaseTA358
Idelalisib for treating chronic lymphocytic leukaemiaTA359
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapyTA352
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolismTA354
Naloxegol for treating opioid‑induced constipationTA345
Aflibercept for treating diabetic macular oedemaTA346
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancerTA347
Everolimus for preventing organ rejection in liver transplantationTA348
Secukinumab for treating moderate to severe plaque psoriasisTA350
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)TA351
Omalizumab for previously treated chronic spontaneous urticariaTA339
Vedolizumab for treating moderately to severely active ulcerative colitisTA342
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA341
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemiaTA343
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndromeTA335
Empagliflozin in combination therapy for treating type 2 diabetesTA336
Rifaximin for preventing episodes of overt hepatic encephalopathyTA337
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapyTA329
Sofosbuvir for treating chronic hepatitis CTA330
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanomaTA269
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA327
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapyTA323
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular blockTA324
Nalmefene for reducing alcohol consumption in people with alcohol dependenceTA325
Imatinib for the adjuvant treatment of gastrointestinal stromal tumoursTA326
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular blockTA88
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanomaTA321
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromesTA317
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaTA319
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failureTA314
Canagliflozin in combination therapy for treating type 2 diabetesTA315
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitisTA308
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaTA306
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young peopleTA300
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)TA302
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis CTA106
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis CTA75
Pazopanib for the first-line treatment of advanced renal cell carcinomaTA215
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorderTA292
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolismTA287
Mirabegron for treating symptoms of overactive bladderTA290
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)TA286
Omalizumab for treating severe persistent allergic asthmaTA278
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fracturesTA279
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosisTA276
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)TA277
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tractTA272
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)TA273
Ipilimumab for previously treated advanced (unresectable or metastatic) melanomaTA268
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)TA270
Dronedarone for the treatment of non-permanent atrial fibrillationTA197
Mannitol dry powder for inhalation for treating cystic fibrosisTA266
Ivabradine for treating chronic heart failureTA267
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumoursTA265
Alteplase for treating acute ischaemic strokeTA264
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolismTA261
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2TA257
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Botulinum toxin type A for the prevention of headaches in adults with chronic migraineTA260
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254
Pharmalgen for the treatment of bee and wasp venom allergyTA246
Tocilizumab for the treatment of rheumatoid arthritisTA247
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Rituximab for the first-line treatment of stage III-IV follicular lymphomaTA243
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adultsTA245
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Ticagrelor for the treatment of acute coronary syndromesTA236
Mifamurtide for the treatment of osteosarcomaTA235
Bortezomib and thalidomide for the first‑line treatment of multiple myelomaTA228
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusionTA229
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarctionTA73
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancerTA227
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphomaTA226
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial diseaseTA223
Golimumab for the treatment of psoriatic arthritisTA220
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 yearsTA213
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular eventsTA210
Prucalopride for the treatment of chronic constipation in womenTA211
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Trastuzumab for the treatment of HER2-positive metastatic gastric cancerTA208
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumoursTA209
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumoursTA86
Denosumab for the prevention of osteoporotic fractures in postmenopausal womenTA204
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)TA207
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis CTA200
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemiaTA193
Capecitabine for the treatment of advanced gastric cancerTA191
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Human growth hormone (somatropin) for the treatment of growth failure in childrenTA188
Infliximab and adalimumab for the treatment of Crohn's diseaseTA187
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromesTA47
Topotecan for the treatment of relapsed small-cell lung cancerTA184
Topotecan for the treatment of recurrent and stage IVB cervical cancerTA183
Guidance on the use of electroconvulsive therapyTA59
Sunitinib for the treatment of gastrointestinal stromal tumoursTA179
Pemetrexed for the first-line treatment of non-small-cell lung cancerTA181
Alitretinoin for the treatment of severe chronic hand eczemaTA177
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178
Tenofovir disoproxil for the treatment of chronic hepatitis BTA173
Rituximab for the first-line treatment of chronic lymphocytic leukaemiaTA174
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adultsTA170
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinomaTA169
Amantadine, oseltamivir and zanamivir for the treatment of influenzaTA168
Machine perfusion systems and cold static storage of kidneys from deceased donorsTA165
Infliximab for acute exacerbations of ulcerative colitisTA163
Spinal cord stimulation for chronic pain of neuropathic or ischaemic originTA159
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adultsTA157
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenzaTA158
Routine antenatal anti-D prophylaxis for women who are rhesus D negativeTA156
Entecavir for the treatment of chronic hepatitis BTA153
Telbivudine for the treatment of chronic hepatitis BTA154
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitusTA151
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)TA149
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neckTA145
Adalimumab for the treatment of adults with psoriasisTA146
Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and overTA138
Structural neuroimaging in first-episode psychosisTA136
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphomaTA137
Infliximab for the treatment of adults with psoriasisTA134
Pemetrexed for the treatment of malignant pleural mesotheliomaTA135
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 yearsTA131
Bortezomib monotherapy for relapsed multiple myelomaTA129
Stapled haemorrhoidopexy for the treatment of haemorrhoidsTA128
Pemetrexed for the treatment of non-small-cell lung cancerTA124
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Varenicline for smoking cessationTA123
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade gliomaTA121
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemiaTA119
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapyTA117
Methadone and buprenorphine for the management of opioid dependenceTA114
Naltrexone for the management of opioid dependenceTA115
Gemcitabine for the treatment of metastatic breast cancerTA116
Laparoscopic surgery for colorectal cancerTA105
Etanercept and efalizumab for the treatment of adults with psoriasisTA103
Docetaxel for the treatment of hormone-refractory metastatic prostate cancerTA101
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancerTA100
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis BTA96
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries)TA92
Guidance on the use of paclitaxel in the treatment of ovarian cancerTA55
Laparoscopic surgery for inguinal hernia repairTA83
Tacrolimus and pimecrolimus for atopic eczemaTA82
Frequency of application of topical corticosteroids for atopic eczemaTA81
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomniaTA77
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleedingTA78
Pre-hospital initiation of fluid replacement therapy in traumaTA74
Guidance on the use of liquid-based cytology for cervical screeningTA69
Human growth hormone (somatropin) in adults with growth hormone deficiencyTA64
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancerTA61
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarctionTA52
Guidance on the use of ultrasound locating devices for placing central venous cathetersTA49
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)TA38
Guidance on the use of trastuzumab for the treatment of advanced breast cancerTA34
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemiaTA29
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone diseaseTA20
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthmaTA10
Guidance on the extraction of wisdom teethTA1

Results per page

  1. 10
  2. 25
  3. 50
  4. All